Retrophin, Inc. (RTRX) News

Retrophin, Inc. (RTRX): $24.25

0.11 (-0.45%)

POWR Rating

Component Grades








Add RTRX to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




in industry

Filter RTRX News Items

RTRX News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

Latest RTRX News From Around the Web

Below are the latest news stories about Retrophin Inc that investors may wish to consider to help them evaluate RTRX as an investment opportunity.

Retrophin enrolls patients for the study of sparsentan in IgA nephropathy

Retrophin (RTRX) announced that the first 280 patients have been enrolled in the pivotal Phase 3 PROTECT Study evaluating the safety and efficacy of sparsentan in IgA nephropathy.Topline efficacy data from the 36-week proteinuria endpoint analysis are expected in Q3 2021. "As a result of achieving this important enrollment milestone...

Seeking Alpha | September 21, 2020

BofA bullish on Retrophin, sees 56% upside

BofA analyst Scott Puckhaber has initiated coverage on Retrophin ([[RTRX]] +3.9%) with a Buy rating and $30 (56% upside) price target.Topline data from two Phase 3 clinical trials evaluating lead candidate sparsentan are expected in H2 2021 in two kidney indications, ahead of previous guidance of H1 2022 mentioned in its Q2...

Seeking Alpha | August 24, 2020

Retrophin, Inc. (RTRX) CEO Eric Dube on Q2 2020 Results - Earnings Call Transcript

Retrophin, Inc. (RTRX) Q2 2020 Earnings Conference Call July 30, 2020 16:30 ET Company Participants Chris Cline - Vice President, Investor Relations and Corporate Communications Eric Dube - Chief Executive Officer Noah Rosenberg - Chief Medical Officer Peter Heerma - Chief Commercial Officer Laura Clague - Chief Financial Officer Bill...

SA Transcripts on Seeking Alpha | August 3, 2020

Retrophin to Present at Upcoming Investor Conferences

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will participate in the following…

GlobeNewswire | August 3, 2020

Retrophin Reports Second Quarter 2020 Financial Results

Enrollment ahead of schedule in Phase 3 PROTECT Study of sparsentan in IgAN; topline proteinuria data from both pivotal studies in FSGS and IgAN now…

GlobeNewswire | July 30, 2020

Retrophin (RTRX) Reports Q2 Loss, Misses Revenue Estimates

Retrophin (RTRX) delivered earnings and revenue surprises of 0.00% and -0.14%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | July 30, 2020

Retrophin (RTRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Retrophin (RTRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 23, 2020

The Daily Biotech Pulse: Aurinia's Kidney Inflammation Drug Filing Accepted For Review, Intuitive Surgical's Q2 Beat

Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 21) ABIOMED, Inc. (NASDAQ: ABMD ) Assembly Biosciences Inc (NASDAQ: ASMB ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Beigene Ltd (NASDAQ: BGNE ) BioLife Solutions Inc (NASDAQ: BLFS ) BioMarin Pharmaceutical Inc. (NASDAQ: BMRN ) Brainstorm Cell Therapeutics Inc (NASDAQ: BCLI ) Catalent Inc (NYSE: CTLT ) CTI BioPharma Corp (NASDAQ: CTIC ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Heat Biologics Inc (NASDAQ: HTBX ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Ligand Pharmaceuticals Inc. (NASDAQ: LGND ) Natera Inc (NASDAQ: NTRA ) Novo Nordisk A/S (NYSE: NVO ) Opko Health Inc. (NASDAQ: OPK )(moved in reaction to an announcement it will offer ...

Benzinga | July 22, 2020

Did Hedge Funds Make The Right Call On Retrophin Inc (RTRX) ?

The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of March 31st, a week after the market trough. Now, we are […]

Yahoo | July 20, 2020

Retrophin to Report Second Quarter 2020 Financial Results

SAN DIEGO, July 16, 2020 -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report second quarter 2020 financial results on Thursday, July 30, 2020 after the close of.

Yahoo | July 16, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!